Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market By Type (Stimulants (Methylphenidate, Dextroamphetamine, Amphetamine, and Others) and Non-Stimulants (Atomoxetine, Guanfacine, Bupropion, and Others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Speciality Clinics, and e-Commerce), Industry Trends, Estimation & Forecast, 2023-2030

Market Definition

Attention Deficit Hyperactivity Disorder (ADHD) drugs are used for the treatment of attention deficit hyperactivity disorder (ADHD). Some of the medications for ADHD include methylphenidate, Dexamfetamine, lisdexamfetamine, atomoxetine, guanfacine, and others. The medications help with the condition concentrate better, be less impulsive, feel calmer, and learn and practice new skills.

The Attention Deficit Hyperactivity Disorder (ADHD) Drugs market was valued at 13.4 billion US$ in 2022 and is projected to reach 19.1 billion US$ by 2030, at a CAGR of 4.5% during the forecast period.

Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Revenue By, 2022-2030

Market Dynamics

The rising prevalence of attention deficit hyperactivity disorder is a key driving factor in the market. For instance, according to the Centers for Disease Control and Prevention (CDC), the prevalence of adult attention deficit hyperactivity disorder (ADHD) is estimated at 2.8% globally. More than 6.1 million children in the United States age between 2 to 17 are estimated to have ADHD in 2017, of which 388,000 of young children are aged between 2 to 5 years, 2.4 million of children are aged between 6 to 11 years, and 3.3 million of children are aged between 12 to 17 years. According to the Attention Deficit Disorder Association, 11 million adults in the U.S. have attention deficit hyperactivity disorder (ADHD). Further, increasing clinical studies for attention deficit hyperactivity disorder (ADHD) drugs is driving the market demand. For instance, Otsuka Pharmaceutical Development & Commercialization, Inc., has completed phase 3 clinical trials for the efficacy, safety, and tolerability of oral centanafadine. Centanafadine is a novel investigational compound for the treatment of the adult with attention-deficit hyperactivity disorder (ADHD). However, the side effect of attention deficit hyperactivity disorder (ADHD) drugs might hamper the market growth. Some of the common side effects of attention deficit hyperactivity disorder (ADHD) drugs include insomnia, nausea, decreased appetite, anorexia, weight loss, headache, elevated pulse, increased blood pressure, abdominal pain, and mood lability. Moreover, increasing awareness regarding attention deficit hyperactivity disorder (ADHD) would provide lucrative opportunities for the market in the coming years.

Market Segmentation

The global attention deficit hyperactivity disorder (ADHD) drugs market is mainly classified based on type and distribution channels. Type is further segmented into Stimulants (Methylphenidate, Dextroamphetamine, Amphetamine, and Others) and Non-Stimulants (Atomoxetine, Guanfacine, Bupropion, and Others). By distribution channel, the market is divided into Hospital Pharmacies, Retail Pharmacies, Speciality Clinics, and e-Commerce.

Stimulant accounted for the largest share in the attention deficit hyperactivity disorder (ADHD) drugs market in 2019 and is expected to dominance in the forecast period. The increasing clinical studies on attention deficit hyperactivity disorder (ADHD) drugs, and government support for the use of stimulants ADHD drugs in the treatment of attention deficit hyperactivity disorder (ADHD), and regulatory approval of attention deficit hyperactivity disorder (ADHD) drugs are some of the factors driving the market demand. For instance, Adlon Therapeutics L.P. has received the U.S. Food and Drug Administration (FDA) approval for Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII, for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in patients six years and older.

Regional Analysis

Based on geography, the global attention deficit hyperactivity disorder (ADHD) drugs market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America was dominating the attention deficit hyperactivity disorder (ADHD) drugs market in 2019, owing to the rising incidence of ADHD, research and development activity for ADHD drugs, and commercialization of regulatory approved ADHD drugs. For instance, Shire has introduced MYDAYIS for patients 13 years and older with Attention Deficit Hyperactivity Disorder (ADHD). Shire commercializes Mydayis in the United States market.

Competitive landscape

Key players operating in the attention deficit hyperactivity disorder (ADHD) drugs industry include Novartis AG, Pfizer, Eli Lily & Company, Johnson & Johnson Services, LLC, Lupin, Purdue Pharma L.P., GlaxoSmithKline PLC, Hisamitsu Pharmaceutical Co., Inc., and Mallinckrodt, UCB S.A.

The development of attention deficit hyperactivity disorder (ADHD) drugs with the wider application by the companies, commercialization of regulatory approved ADHD drugs, rising clinical studies on ADHD drugs, and the collaboration between companies to develop attention deficit hyperactivity disorder (ADHD) drugs and expand the market presence are some of the strategies adopted by the prominent players. For instance, Adare Pharmaceuticals, Inc. (Adare) has collaborated with NLS Pharmaceutics Ltd. (NLS) to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder (ADHD).

Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Key Segments:

By Type
• Stimulants
o Methylphenidate
o Dextroamphetamine
o Amphetamine
o Others
• Non-Stimulants
o Atomoxetine
o Guanfacine
o Bupropion
o Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Clinics
• e-Commerce

Major Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Industry Players
• Novartis AG
• Pfizer
• Eli Lily & Company
• Johnson & Johnson Services, LLC
• Lupin
• Purdue Pharma L.P.
• GlaxoSmithKline PLC
• Hisamitsu Pharmaceutical Co., Inc.
• Mallinckrodt
• UCB S.A.

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Rising Prevalence of Attention Deficit Hyperactivity Disorder
3.4. Restraints
3.4.1. Side Effect of Attention Deficit Hyperactivity Disorder (ADHD) Drugs
3.5. Opportunity
3.5.1. Increasing Awareness Regarding Attention Deficit Hyperactivity Disorder (ADHD)
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Stimulants
4.2.1. Market Size & Forecast
4.2.1.1. Methylphenidate
4.2.1.1.1. Market Size & Forecast
4.2.1.2. Dextroamphetamine
4.2.1.2.1. Market Size & Forecast
4.2.1.3. Amphetamine
4.2.1.3.1. Market Size & Forecast
4.2.1.4. Others
4.2.1.4.1. Market Size & Forecast
4.3. Non-Stimulants
4.3.1. Market Size & Forecast
4.3.1.1. Atomoxetine
4.3.1.1.1. Market Size & Forecast
4.3.1.2. Guanfacine
4.3.1.2.1. Market Size & Forecast
4.3.1.3. Bupropion
4.3.1.3.1. Market Size & Forecast
4.3.1.4. Others
4.3.1.4.1. Market Size & Forecast

5. Distribution Channel Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Hospital Pharmacies
5.2.1. Market Size & Forecast
5.3. Retail Pharmacies
5.3.1. Market Size & Forecast
5.4. Specialty Clinics
5.4.1. Market Size & Forecast
5.5. e-Commerce
5.5.1. Market Size & Forecast

6. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Distribution Channel
6.2.4. U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Distribution Channel
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Distribution Channel
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Distribution Channel
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By Distribution Channel
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. Novartis AG
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. Novartis AG Product Category, Application, and Specification
7.1.3. Novartis AG Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Pfizer
7.3. Eli Lily & Company
7.4. Johnson & Johnson Services, LLC
7.5. Lupin
7.6. Purdue Pharma L.P.
7.7. GlaxoSmithKline PLC
7.8. Hisamitsu Pharmaceutical Co., Inc.
7.9. Mallinckrodt
7.10. UCB S.A.